Afamelanotide for treating erythropoietic protoporphyria

  • Highly specialised technologies guidance
  • HST27
  • Published: 

Notice of Appeal

Afamelanotide for treating erythropoietic protoporphyria [ID927]

This appeal hearing will hear appeals against the Final Evaluation Document for the above technology by the following organisations:

  • CLINUVEL Group
  • International Porphyria Patient Network (IPPN)

The appeal panel will convene on Monday 15 May 2023 at 10.00am via Zoom to hear oral representations from the appellants.

 

This page was last updated: